Safety of live attenuated herpes zoster vaccine in Australian adults 70-79 years of age: An observational study using active surveillance

To assess the safety of live attenuated herpes zoster vaccine live (ZVL) through cumulative analysis of near real-time, participant-based active surveillance from Australia's AusVaxSafety system. ZVL was funded in Australia for adults aged 70 years from November 2016, with a time-limited catch up programme for those up to 79 years. This cohort study monitored safety in the first two programme years through active surveillance at 246 sentinel surveillance immunisation sites.

Citation:
Phillips A, Glover C, Leeb A, Cashman P, Fathima P, Crawford N, et al. Safety of live attenuated herpes zoster vaccine in Australian adults 70-79 years of age: An observational study using active surveillance. BMJ Open. 2021;11(3).

Keywords:
Adverse events; preventive medicine; primary care; public health

Abstract:
To assess the safety of live attenuated herpes zoster vaccine live (ZVL) through cumulative analysis of near real-time, participant-based active surveillance from Australia's AusVaxSafety system. ZVL was funded in Australia for adults aged 70 years from November 2016, with a time-limited catch up programme for those up to 79 years. This cohort study monitored safety in the first two programme years through active surveillance at 246 sentinel surveillance immunisation sites.